AstraZeneca PLC (AZN)
| Market Cap | 280.17B +36.5% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 26.97 |
| Forward PE | 17.02 |
| Dividend | $3.20 (1.78%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 2,892,240 |
| Open | 182.72 |
| Previous Close | 185.67 |
| Day's Range | 179.62 - 183.23 |
| 52-Week Range | 134.90 - 212.71 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 224.49 (+24.92%) |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.49, which is an increase of 24.92% from the latest price.
News
5 Foreign Stocks That Could Beat The S&P 500
James Demmert explains why foreign markets are beating the U.S.—and the five international stocks he thinks can outperform the S&P 500.
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s (AZN) Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolization, TACE, demonstrated a statistically si...
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transa...
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it w...
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
The company states: “The global CARES Phase 3 clinical programme showed that treatment with anselamimab, a potential first-in-class anti-fibril therapy, resulted in nominally statistically significant...
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca Imfinzi combination approved in the U.S.
AstraZeneca’s (AZN) Imfinzi in combination with Bacillus Calmette-Guerin induction and maintenance therapy has been approved in the U.S. for the treatment of adult patients with BCG-naive, high-risk n...
FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) announced that its IMFINZI (durvalumab), in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, has been approve...
AstraZeneca’s durvalumab approved in U.S. for NMIBC patients
The company states: “AstraZeneca’s (AZN) IMFINZI – or durvalumab – in combination with Bacillus Calmette-Guerin – BCG – induction and maintenance therapy has been approved in the US for the…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatmen...
AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy
AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy
AstraZeneca confirms FDA approves Imfinzi combo for bladder cancer
AstraZeneca’s (AZN) Imfinzi in combination with Bacillus Calmette-Guerin induction and maintenance therapy has been approved in the U.S. for the treatment of adult patients with BCG-naive, high-risk n...
FDA approves durvalumab combo for high-risk non-muscle invasive bladder cancer
The Food and Drug Administration approved durvalumab, or Imfinzi, from AstraZeneca (AZN), in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naive, high-risk non...
AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment
AZN's Patent Granted in Canada Strengthens Position in Male Infertility Treatment
AstraZeneca (AZN) Receives FDA Extension for Drug Review
AstraZeneca (AZN) Receives FDA Extension for Drug Review
AstraZeneca says FDA extends PDUFA date to review camizestrant data for NDA
The US Food and Drug Administration, FDA, has informed AstraZeneca (AZN) that it will extend the Prescription Drug User Fee Act, PDUFA, date to review additional data requested to support…
FDA Extends Review Of AstraZeneca's Camizestrant NDA In ESR1-Mutated Advanced Breast Cancer
(RTTNews) - AstraZeneca (AZN, AZN.L) announced that the US Food and Drug Administration or FDA will extend the PDUFA date to review additional data requested to support the New Drug Application or NDA...
AstraZeneca: FDA Extends PDUFA Date Related To NDA For Camizestrant
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the FDA has informed that it will extend the PDUFA date to review additional data requested to support the New Drug Application for camizestra...
US FDA extends review of AstraZeneca's experimental breast cancer pill
AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended its review deadline for its experimental breast cancer pill camizestrant to assess additional data.
Top losers in morning trade: gujarat state petronet at ₹268.35 down 7.13%, techno electric at ₹1,121.80 slips 6.61%, astrazeneca at ₹8,383.00 falls 6.47%
The Indian stock market showed mixed signals this morning with the SENSEX slightly up by 0.18% at 76,143.21 and the NIFTY 50 rising by 0.21% to 23,963.85. However, certain stocks…
AstraZeneca PLC: US FDA decision date on camizestrant extended
27 May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administration (FDA) has informed AstraZeneca that it will ext...
How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
Inside a pharmaceutical plant, heat is everywhere—and until recently, almost nobody was paying attention to it.